Genetics in clinical cancer care: A promise unfulfilled among minority populations

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 11, 2004, Pages 1683-1686

  Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; BREAST CANCER; CANCER CONTROL; CANCER GENETICS; CANCER REGISTRY; CANCER RISK; DELETION MUTANT; EDITORIAL; ETHNIC GROUP; GENETIC COUNSELING; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; INSURANCE; MINORITY GROUP; ONCOGENE; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AGED; BREAST NEOPLASMS; DATABASES, FACTUAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HUMANS; MINORITY GROUPS; REGISTRIES;

EID: 8344244571     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14;1730-6.
2. Miki Y, Swensen J, Shattuck-Eidens Futreal PA, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
3. Pal T, Permuth-Wey J, Holtje T, Sutphen R. BRCA1 and BRCA2 mutations in African American Breast Cancer patients. Cancer Epidemiol Biomarkers Prev 2004;13, this issue.
4. Mefford HC, Baumbach L, Panguluri RC, et al. Evidence for a BRCA1 founder mutation in families of West African ancestry. Am J Hum Genet 1999;65:575-8.
5. Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI. Germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet 1997;60:1233-6.
6. Gao Q, Tomlinson G, Das S, et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000;107:186-91. Erratum in: Hum Genet 2001; 109:239-40.
7. Shen D, Wu Y, Subbarao M, Bhat H, Chillar R, Vadgama JV. Mutation analysis of BRCA1 gene in African-American patients with breast cancer. J Natl Med Assoc January 2000;92:29-35.
8. Panguluri RC, Brody LC, Modali R, et al. BRCA1 mutations in African Americans. Hum Genet 1999;105:28-31.
9. Frank T, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
10. An Open Access Online Breast Cancer Mutation Database. Bethesda (MD): National Human Genome Research Institute; 2002. Available from: http://www.nhgri.nih.gov.
11. Nanda R, Schumm P, Cummings S, Hagos F, et al. Olopade genetic testing in an ethnically diverse cohort of high risk women: a comparative analysis of BRCA1 and BRCA2 genes in families of European and African ancestry [abstract 3435], ASCO Proc 2003;22:855.
12. Wagner TM, Hirtenlehner K, Shen P, et al. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet April 1999; 8:717-9.
13. Fackenthal JD, Sveen L, Gao Q, et al. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. Am J Med Genet. In press.
14. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Breast Cancer Information Core (BIC) Steering Committee. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44. Epub 2004 Aug 02.
15. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol May 1, 2004;22:1638-45.
16. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
17. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
18. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
19. Antoniou A, Pharaoh PD. Narod: average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case 20. Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
20. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-7.
21. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation [comment]. N Engl J Med 2001;345:159-64.
22. Kinney AY, Emery G, Dudley WN, Croyle RT. Screening behaviors among African American women at high risk for breast cancer: do beliefs about god matter? Oncol Nurs Forum 2002;29:835-43.
23. Kriege M, Brekelman CT, Boetes C, et al. Efficacy of MRI and Mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
24. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations [comment]. N Engl J Med 2002;346:1616.
25. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation [comment]. N Engl J Med 2002;346:1609.
26. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD. Health insurance concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79-87.
27. Kuerer HM, Hwang ES, Anthony JP, et al. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol 2000;7:325.
28. Kauff ND, Scheuer L, Robson ME, et al. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 2001;3:422.